Rosuvastatin: Difference between revisions
David Canner (talk | contribs) No edit summary |
No edit summary |
||
| (5 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
< | <StructureSection load='' size='340' side='right' caption='Rosuvastatin, also known as Crestor' scene='User:David_Canner/Sandbox_crestor/Rosu/1'> | ||
===Better Known as: Crestor=== | ===Better Known as: Crestor=== | ||
* Marketed By: AstraZeneca Plc.<br /> | * Marketed By: AstraZeneca Plc.<br /> | ||
| Line 6: | Line 6: | ||
* Date of FDA Approval (Patent Expiration): 2003 (2016)<br /> | * Date of FDA Approval (Patent Expiration): 2003 (2016)<br /> | ||
* 2009 Sales: $4.5 Billion <ref>http://www.reuters.com/article/idUSN2223558720100222</ref> | * 2009 Sales: $4.5 Billion <ref>http://www.reuters.com/article/idUSN2223558720100222</ref> | ||
* | * Importance: Sales of Crestor are the fastest growing among the statins. Statins are so ubiquitous, doctors have even suggested handing them out with fast food. See: [http://www.bbc.co.uk/news/health-10955522 the article] <br /> | ||
* | * See [[Pharmaceutical Drugs]] for more information about other drugs and disorders | ||
===Mechanism of Action=== | ===Mechanism of Action=== | ||
[[Rosuvastatin]] is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a <scene name='Rosuvastatin/Statin_rosu/2'>highly regulated enzyme</scene> responsible for the committed step in cholesterol synthesis. Rosuvastatin, like most of the statins, <scene name='HMG-CoA_Reductase/Statin_rosu/6'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Rosuvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Rosuvastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref> | [[Rosuvastatin]] is an inhibitor of [[HMG-CoA Reductase]] (HMGR), a <scene name='Rosuvastatin/Statin_rosu/2'>highly regulated enzyme</scene> responsible for the committed step in cholesterol synthesis. Rosuvastatin, like most of the statins, <scene name='HMG-CoA_Reductase/Statin_rosu/6'>binds HMGR</scene> via a number of polar interactions with the "cis loop" of HMGR, particularly residues Ser 684, Asp 690, Lys 691, Lys 692, and hydrogen bond interactions between Glu 559 and Asp 767 with the O5-hydroxyl of the statins. Van der Waals interactions between Leu 562, Val 683, Leu 853, Ala 856, and Leu 857 of HMGR and hydrophobic ring structures of Rosuvastatin contribute to binding as well.<ref>PMID:11349148</ref> These interactions help Rosuvastatin outcompete HMG-CoA, the substrate of HMGR, in binding to HMGR.<ref>PMID:7784310</ref> | ||
</StructureSection> | |||
===Pharmacokinetics=== | ===Pharmacokinetics=== | ||
<table style="background: cellspacing="0px" align="" cellpadding="0px" width="42%"> | |||
<tr> | |||
<td style="width:100%; vertical-align:top;border-width:0px; border-style:inset"> | |||
<div style="height:100%; width: 100%"> | |||
{{:Statin Pharmacokinetics}} | |||
</div> | |||
</td> | |||
</tr> | |||
</table> | |||
===Effectiveness and Side Effects=== | ===Effectiveness and Side Effects=== | ||